These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results

AbbVie Inc. (NYSE:ABBV) on Friday reported better-than-expected third-quarter 2026 results and raised its full-year outlook.

AbbVie reported third-quarter sales of $17.404 billion, up 10.3% year over year on a reported basis and 10.5% on an operational basis, beating the Wall Street estimate of $17.314 billion. Adjusted earnings of $3.82 per share topped the analyst consensus estimate of $3.75.

"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert Michael, chairman and CEO.

AbbVie raised its full-year 2026 revenue forecast to $67.8 billion from $67.6 billion, above the Wall Street estimate of $67.585 billion. The company raised its 2026 adjusted earnings forecast to $13.95-$13.99 per share from $13.76-$13.96, above the analyst consensus estimate of $13.93.

AbbVie shares rose 0.1% to $295.15 in pre-market trading.

These analysts made changes to their price targets on AbbVie following earnings announcement.

• Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $290 to $325.
• Canaccord Genuity analyst Gary Nachman maintained the stock with a Buy and boosted the price target from $290 to $338.
• RBC Capital analyst Trung Huynh maintained the stock with an Outperform rating and lifted the price target from $280 to $330.

Considering buying ABBV stock? Here’s what analysts think:

Photo via Shutterstock